Literature DB >> 17998299

Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes.

Bing Zhu1, David Bush, George A Doss, Stella Vincent, Ronald B Franklin, Shiyao Xu.   

Abstract

Midazolam is a potent benzodiazepine derivative with sedative, hypnotic, anticonvulsant, muscle-relaxant, and anxiolytic activities. It undergoes oxidative metabolism catalyzed almost exclusively by the CYP3A subfamily to a major metabolite, 1'-hydroxymidazolam, which is equipotent to midazolam. 1'-Hydroxymidazolam is subject to glucuronidation followed by renal excretion. To date, the glucuronidation of 1'-hydroxymidazolam has not been evaluated in detail. In the current study, we identified an unreported quaternary N-glucuronide, as well as the known O-glucuronide, from incubations of 1'-hydroxymidazolam in human liver microsomes enriched with uridine 5'-diphosphoglucuronic acid (UDPGA). The structure of the N-glucuronide was confirmed by nuclear magnetic resonance analysis, which showed that glucuronidation had occurred at N-2 (the imidazole nitrogen that is not a part of the benzodiazepine ring). In a separate study, in which midazolam was used as the substrate, an analogous N-glucuronide also was detected from incubations with human liver microsomes in the presence of UDPGA. Investigation of the kinetics of 1'-hydroxymidazolam glucuronidation in human liver microsomes indicated autoactivation kinetics (Hill coefficient, n = 1.2-1.5). The apparent S(50) values for the formation of O- and N-glucuronides were 43 and 18 microM, respectively, and the corresponding apparent V(max) values were 363 and 21 pmol/mg of microsomal protein/min. Incubations with recombinant human uridine diphosphate glucuronosyltransferases (UGTs) indicated that the O-glucuronidation was catalyzed by UGT2B4 and UGT2B7, whereas the N-glucuronidation was catalyzed by UGT1A4. Consistent with these observations, hecogenin, a selective inhibitor of UGT1A4, selectively inhibited the N-glucuronidation, whereas diclofenac, a potent inhibitor of UGT2B7, had a greater inhibitory effect on the O-glucuronidation than on the N-glucuronidation. In summary, our study provides the first demonstration of N-glucuronidation of 1'-hydroxymidazolam in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17998299     DOI: 10.1124/dmd.107.017962

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.

Authors:  Pierre-Eric Juif; Margaux Boehler; Yves Donazzolo; Shirin Bruderer; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2017-06-21       Impact factor: 2.953

2.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

3.  Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping.

Authors:  Bettina Link; Manuel Haschke; Nathalie Grignaschi; Michael Bodmer; Yvonne Zysset Aschmann; Markus Wenk; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2008-04-11       Impact factor: 4.335

4.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

5.  Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates.

Authors:  Maurice J Ahsman; Manon Hanekamp; Enno D Wildschut; Dick Tibboel; Ron A A Mathot
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

6.  Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach.

Authors:  Dan-Dan Tian; Cathrine Leonowens; Emily J Cox; Vanessa González-Pérez; Kosea S Frederick; Yolanda V Scarlett; Michael B Fisher; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2019-04-26       Impact factor: 3.922

7.  CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice.

Authors:  A S Gandhi; T Guo; P Shah; B Moorthy; D S-L Chow; M Hu; R Ghose
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

8.  Study of the fragmentation of arginine isobutyl ester applied to arginine quantification in Aedes aegypti mosquito excreta.

Authors:  David R Bush; Vicki H Wysocki; Patricia Y Scaraffia
Journal:  J Mass Spectrom       Date:  2012-10       Impact factor: 1.982

9.  CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans.

Authors:  Niladri Chattopadhyay; Tobias Kanacher; Manuela Casjens; Sebastian Frechen; Sandra Ligges; Torsten Zimmermann; Antje Rottmann; Bart Ploeger; Joachim Höchel; Marcus-Hillert Schultze-Mosgau
Journal:  Br J Clin Pharmacol       Date:  2018-10-11       Impact factor: 4.335

10.  Ontogeny of midazolam glucuronidation in preterm infants.

Authors:  Saskia N de Wildt; Greg L Kearns; Darryl J Murry; Gideon Koren; John N van den Anker
Journal:  Eur J Clin Pharmacol       Date:  2009-10-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.